Article PDF
Avoid common mistakes on your manuscript.
References
FDA Drug Approvals — G. Available at http://www.fda.gov/ cder/approval/g.htm. Accessed September 27,2006.
Nemeroff CB, Lieberman JA, Weiden PJ, et al. From clinical research to clinical practice: a 4-year review of ziprasidone.CNS Spectr. 2005;10(11):S1–20.
Perlis RH, Welge JA, Vornik LA, Hirschfeld RMA, Keck PE. Atypical antipsychotics in the treatment of mania: a metaanalysis of randomized, placebo-controlled trials.J Clin Psychiatry. 2006;67:509–516.
Patel NC, Keck PE. Ziprasidone: efficacy and safety in patients with bipolar disorder.Expert Rev Neurother. 2006;6 (8):1129–1138.
Stimmel GL, Gutierrez MA, Lee V. Ziprasidone: an atypical antipsychotic drug for the treatment of schizophrenia.Clin Ther. 2002;24:21–37.
Barak Y, Mazeh D, Plopski I, Baruch Y. Intramuscular ziprasidone treatment of acute psychotic agitation in elderly patients with schizophrenia.Am J Geriatr Psychiatry. 2006;14 (7):629–633.
Martel M, Sterzinger A, Miner J, Clinton J, Biros M. Management of acute undifferentiated agitation in the emergency department: a randomized double-blind trial of droperidol, ziprasidone, and midazolam.Acad Emerg Med. 2005;12 (12):1167–1172.
Ray WA, Meredith S, Thapa PB; Meador KG, Hall K, Murray KT. Antipsychotics and the risk of sudden cardiac death.Arch Gen Psychiatry. 1991;58:1161–1167.
Hennessy S, Bilker WB, Knauss JS, Margolis DJ, Kimmel SE, Reynolds RF, et al. Cardiac arrest and ventricular arrhythmia in patients taking antipsychotic drugs: cohort study using administrative data.BMJ. 2002;325:1070–1074.
Reilly JG, Ayis SA, Ferrier IN, Jones SJ, Thomas SHL. Thioridazine and sudden unexplained death in psychiatric in-patients.Br J Psychiatry. 2002;180:515–522.
Straus SM, Bleumink GS, Dieleman JP, van der Lei J, ’tJong GW, Kingma JH, et al. Antipsychotics and the risk of sudden cardiac death.Arch Intern Med. 2004;164:1293–1297.
2002 Safety Alert—Geodon (ziprasidone HCl). Available at: http://www.fda.gov/medwatch/SAFETY/2002/geodon.htm. Accessed October 13, 2006.
Alert for healthcare professionals—Ziprasidone (marketed as Geodon). Available at: http://www.fda.gov/cder/drug/ InfoSheets/HCP/ziprasidoneHCP.htm. Accessed September 27,2006.
Geodon product information.Physicians’ desk reference. 58th ed. Montvale, NJ: Thomson PDR,2004:2597–2603.
Glassman AH, Bigger JT Jr. Antipsychotic drugs: prolonged QTc interval, torsade de pointes, and sudden death.Am J Psychiatry. 2001;158(11):1774–1782.
Kelly DL, Love RC. Ziprasidone and the QTc interval: pharmacokinetic and pharmacodynamic considerations.Psychopharmacol Bull. 2001 (Autumn);35(4):66–79.
Glassman AH. Schizophrenia, antipsychotic drugs, and cardiovascular disease.J Clin Psychiatry. 2005;66 Suppl 6:5–10.
Goodnick PJ. Ziprasidone: profile on safety.Expert Opin Pharmacother. 2001;2(10):1655–1662.
Citrome L, Volavka J. The promise of atypical antipsychotics: fewer side effects mean enhanced compliance and improved functioning.Postgrad Med. 2004;116(4):49–51,55–9,63.
Heinrich TW, Biblo LA, Schneider A. Torsades de pointes associated with ziprasidone.Psychosomatics. 2006;47(3):264–268.
Scahill L, Blair J, Leckman JF, Martin A. Sudden death in a patient with Tourette syndrome during a clinical trial of ziprasidone.J Psychopharmacol. 2005;19(2):205–206.
Bazett H. An analysis of the time relationship of electrocardiograms.Heart.1920;7:353–370.
Sanguinetti MC, Jiang C, Curran ME, Keating MT. A mechanistic link between an inherited and an acquired cardiac arrhythmia: HERG encodes the Ikr potassium channel.Cell.1995;81:299–307.
Juurlink D. Antipsychotics. In: Flomenbaum NE, Goldfrank LR, Hoffman RS, Howland MA, Lewin NA, Nelson LS (editors):Goldfrank’s Toxicologic Emergencies. McGraw-Hill: 8th ed., pp. 1040–1043.
Harrigan EP, Miceli JJ, Anziano R, Watsky E, Reeves KR, Cutler NR, et al. A randomized evaluation of the effects of six antipsychotic agents on QTc, in the absence and presence of metabolic inhibition.J Clin Psychopharmacol. 2004;24:62–69.
Citrome L, Volavka J, Czobor P, Brooks S, Loebel A, Mandel FS. Efficacy of ziprasidone against hostility in schizophrenia: Post hoc analysis of randomized, open-label study data.J Clin Psychiatry. 2006;67(4):638–642.
Justo D, Prokhorov V, Heller K, Zeltser D. Torsade de pointes induced by psychotropic drugs and the prevalence of its risk factors.Acta Psychiatr Scand. 2005:111:171–176.
Roden DM. Drug-induced prolongation of the QT interval.N Eng J Med. 2004;350:1013–1022.
Sartori M, Pratt CM, Young JB. Torsade de pointe. Malignant cardiac arrhythmia induced by amantadine poisoning.Am J Med. 1984;77(2):388–391.
Kay GN, Plumb VJ, Arciniegas JG, Henthorn RW, Waldo AL. Torsades de pointes: the long-short initiating sequence and other clinical features: observations in 32 patients.J Am Coll Cardiol. 1983;2:806–817.
Roden DM, Woosley RL, Primm RK. Incidence and clinical features of the quinidine-associated long QT syndrome: implications for patient care.Am Heart J. 1986;111:1088–1093.
Author information
Authors and Affiliations
Corresponding author
Additional information
This case report was previously presented in abstract format at the 27th International Congress of the European Association of Poison Centres and Clinical Toxicologists (Athens, Greece) in May 2007. There was no outside funding of any kind used for this study.
Rights and permissions
About this article
Cite this article
Manini, A.F., Raspberry, D., Hoffman, R.S. et al. QT prolongation and torsades de pointes following overdose of ziprasidone and amantadine. J. Med. Toxicol. 3, 178–181 (2007). https://doi.org/10.1007/BF03160936
Issue Date:
DOI: https://doi.org/10.1007/BF03160936